Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 493-499

  Soiffer, Robert J ^a,b   Murray, Christine ^a   Shapiro, Charles ^a   Collins, Heather ^a   Chartier, Steven ^a   Lazo, Susan ^a   Ritz, Jerome ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NATURAL KILLER CELL; NAUSEA; PRIORITY JOURNAL; RASH; RIGOR; URTICARIA; VOMITING;

ADULT; AGED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0029962067     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rosenberg, S., Lotze, M., Yang, J , Aebersold, P., Linehan, W , Seipp, C., and White, D. Experience with the use of high dose IL-2 in the treatment of 652 cancer patients. Ann. Surg , 210 474-485, 1989.
2. West, W., Tauer, K., Yannelli, J., Marshall, G , Orr, D., Thurman, G., and Oldham, R Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med., 316: 898-905, 1987.
3. Fisher, R., Coltman, C., Doroshow, J., Rayner, A., Hawkins, M. Mier, J., Wiernick, P., McMannis, J., Weiss, G., Margolin, K., Gemlo, B., Huth, D., Parkinson, D., and Paretta, E. Metastatic renal cancer treated with IL-2 and lymphokine-activated killer cells. Ann. Intern. Med., 108: 518-523, 1988
4. Margolin, K., Rayner, A., Hawkins, M., Atkins, M., Dutcher, J , Fisher, R , Weiss, G., Doroshow, J., Jaffe, H., Roper, M., Parkinson, D., Weirnik, P., Creekmore, S., and Boldt, D. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7: 486-498, 1989
5. Siegel, J. P , and Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol., 9: 694-704, 1991.
6. Weidmann, E., Bergmann, L., Stock, J., Kirsten, R., and Mitrou, P. S. Rapid cytokine release in cancer patients treated with interleukin-2. J. Immunother , 12: 123, 1992.
7. Mier, J. W., Vachino, G., Klempner, M. S., Aronson, F. R., Noring, R., Smith, S., Brandon, E. P., Laird, W., and Atkins, M. B. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of acquired neutrophil chemotaxix defect and differential suppression of interleukin-2-associated side effects. Blood, 76: 1933-1940, 1990.
8. Caligiuri, M., Murray, C., Soiffer, R., Klumpp, T., Seiden, M., Cochran, K., Cameron, C., Ish, C., Buchanan, L., Perillo, D., Smith, K., and Ritz, J. Extended continuous infusion of low dose recombinant IL-2 in advanced cancer: prolonged immune modulation without significant toxicity. J. Clin. Oncol., 9: 2110-2119, 1991.
9. Caligiuri, M. A,. Zmuidzinas, A., Manley, T. J., Levine, H., Smith, K. A., and Ritz, J. Functional consequences of IL-2 receptor expression on resting human lymphocytes: identification of a novel NK cell subset with high affinity receptors. J. Exp. Med , 171: 1509-1526, 1990.
10. Caligiuri, M., Murray, C., Robertson, M., Wang, E., Cochran, K., Cameron, C., Schow, P , Ross, M., Klumpp, T., Soiffer, R., Smith, K., and Ritz, J. Selective modulation of human natural killer cells in vivo following prolonged infusion of low-dose recombinant interleukin-2. J. Clin. Invest., 91: 123-132, 1993.
11. Soiffer, R J., Murray, C., Cochran, K., Cameron, C., Wang, E., Schow, P. W., Daley, J. F., and Ritz, J. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood, 79: 517-526, 1992.
12. Whiteside, T., and Herberman, R. The role of natural killer cells in human disease. Clin. Immunol Immunopathol., 52: 1, 1989.
13. Introna, M., and Mantovani. A. Natural killer cells in human solid tumors. Cancer Metastasis Rev., 2, 337, 1983.
14. Fujimiya, Y., Chang, W-C., Bakke, A., Horwitz, D., and Pattengale, P. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. Cancer Immunol. Immunother., 24: 213, 1987.
15. Choe, B , Frost, P., Morrison, N., and Rose, N. Natural killer cell activity of prostatic cancer patients. Cancer Invest., 5: 285, 1987.
16. Hercend, T., Takvorian, T., Nowill, A., Tantravahi, R., Moungeon, P., Anderson, K. C., Murray, C., Bohuon, C., Ythier, A., and Ritz, J. Characterization of natural killer cells with anti-leukemia activity following allogeneic bone marrow transplantation. Blood, 67: 722-728, 1986.
17. Hauch, M., Gazzola, M., Small, T., Bordignon, C., Barnett, L., Cunningham, I., Castro-Malaspina, H., O'Reilly, R., and Keever, C. Anti-leukemia potential of interleukin-2 actuated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood. 75: 2250-2262, 1990.
18. Robertson, M. J., Caligiuri, M A., Manley, T. J., Levine, H , and Ritz, J. Human natural killer cell adhesion molecules: Differential expression after activation and participation in cytolysis. J. Immunol., 145: 3194-3201, 1990.
19. Nagler, A , Lanier, L., and Phillips, L. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J. Exp Med., 171: 1527-1533, 1990.
20. Smith, K. A. Lowest dose interleukin-2 immuntherapy. Blood, 81: 1414-1423, 1993.
21. Voss, S. D., Hong, R., and Sondel, P. R. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood, 83: 626-635, 1994.
22. Nakarai, T , Robertson, M. J., Streuli, M., Wu, Z., Ciardelli, T. L., Smith, K A., and Ritz, J. IL-2 receptor γ chain expression on resting and activated lymphoid cells. J. Exp. Med., in press, 1994.
23. Espinoza-Delgado, I., Ortaldo, J R., Winkler-Pickett, K , Sugamura, L , Varesio, L , and Longo, D. L Expression and role of p75 interleukin 2 receptor on human monocytes. J. Exp Med., 171: 1821-1826, 1990.
24. Rand, T. H., Siberstein, D. S., Kornfeld, H., and Weller, P. F. Human eosinophils, express functional interleukin-2 receptors. J. Clin. Invest., 88: 825-832, 1991.
25. Djeu, J. Y., Liu, J. H., Wei, S., Rui, H , Pearson, C. A., Leonard, W. J , and Blanchard, D. K. Function associated with IL-2 receptor-β on human neutrophils J. Immunol., 150: 960-970, 1993.
26. Soiffer, R. J., Murray, C , Gonin, R., Ritz, J. Effect of low dose Interleukin-2 on disease relapse after T cell depleted allogeneic bone marrow transplantation. Blood, 84: 964-971, 1994.
27. Stone, R., Murray, C., Berg, D., Mayer, R., Ritz, J., and Soiffer, R. Low dose interleukin-2 following intensification with high dose ara-C for acute myelogenous leukemia in first complete remission (Abstract). Blood, 84: 302a, 1994.
28. Kaplan, G., Britton, W. J., Hancock, G. E., Theuvenet, W. J., Smith, K. A., Job, C. K., Roche, P. W., Molloy, A., Burkhardt, R., Barker, J., Pradhan, H. M , and Conn, Z. A. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. J. Exp. Med., 173: 993-1006, 1991.
29. Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Hermann, S., and Ritz, J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells is differentially regulated by NKSF. J Exp. Med., 175: 779-788, 1992.
30. Chehimi, J., and Trichieri, G. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role m infection and acquired immunodeficiency. J. Clin. Immunol., 14: 149-161, 1994.